Tecfidera, Aubagio Preferred RRMS Treatments in Canada, Report Shows
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Multiple Sclerosis Drugs Market Trends, Strategies, And Opportunities In The Market 2021-2030
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Feb 24, 2021 10:41am
Novartis first DTC campaign for relapsing MS drug Kesimpta debuted in January, five months after it got an FDA nod. (Novartis)
Novartis’ first TV ad for Kesimpta offers the prospect of less drama less relapsing multiple sclerosis drama, that is.
During the commercial, phrases representing that drama such as “unpredictable relapses” and “disability progression” pop up around a young woman as she goes about her day. But another issue that pops up on screen infusion days may cause some drama itself.
That s because it s describing rival infusion treatments for MS, including Kesimpta’s chief competitor Ocrevus, a Roche drug that also works by targeting CD20-expressing B-cells.
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis
News provided by
Share this article
Share this article
EXTON, Pa., Jan. 29, 2021 /PRNewswire/ Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering,